Intolerance to angiotensin converting enzyme inhibitors in asthma and the general population:a UK population-based cohort study by Morales, Daniel R. et al.
                                                                    
University of Dundee
Intolerance to angiotensin converting enzyme inhibitors in asthma and the general
population
Morales, Daniel R.; Lipworth, Brian J.; Donnan, Peter T.; Wang, Huan
Published in:






Version created as part of publication process; publisher's layout; not normally made publicly available
Link to publication in Discovery Research Portal
Citation for published version (APA):
Morales, D. R., Lipworth, B. J., Donnan, P. T., & Wang, H. (2021). Intolerance to angiotensin converting enzyme
inhibitors in asthma and the general population: a UK population-based cohort study. The Journal of Allergy and
Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2021.04.055
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 24. May. 2021
Journal Pre-proof
Intolerance to angiotensin converting enzyme inhibitors in asthma and the general
population: a UK population-based cohort study





To appear in: The Journal of Allergy and Clinical Immunology: In Practice
Received Date: 24 August 2020
Revised Date: 21 April 2021
Accepted Date: 22 April 2021
Please cite this article as: Morales DR, Lipworth BJ, Donnan PT, Wang H, Intolerance to angiotensin
converting enzyme inhibitors in asthma and the general population: a UK population-based cohort
study, The Journal of Allergy and Clinical Immunology: In Practice (2021), doi: https://doi.org/10.1016/
j.jaip.2021.04.055.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2021 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology
1 
 
Intolerance to angiotensin converting enzyme inhibitors in asthma and the 1 
general population: a UK population-based cohort study  2 
 3 
Daniel R. Morales PhD, 1Division of Population Health and Genomics, University of Dundee, UK. 2Health 4 
Data Research (HDR)-UK Scotland. 3Department of Public Health, University of Southern Denmark.  5 
Brian J. Lipworth MD, Scottish Centre for Respiratory Research, University of Dundee, UK 6 
Peter T. Donnan PhD, 1Division of Population Health and Genomics, University of Dundee, UK. 2Dundee 7 
and Epidemiology Biostatistics Unit, University of Dundee, UK 8 
Huan Wang PhD, Division of Population Health and Genomics, University of Dundee, UK 9 
 10 
Corresponding authors 11 
Daniel R. Morales / Brian J Lipworth, Division of Population Health and Genomics, University of Dundee, 12 
Mackenzie Building, Kirsty Semple Way, Dundee, DD2 4BF. Tel: 01382 383475  13 
Email: d.r.z.morales@dundee.ac.uk / b.j.lipworth@dundee.ac.uk  14 
 15 
Short running title: Intolerance to ACE inhibitors in asthma 16 
Word count: 2993 17 
Funding/Conflict of interests 18 
The project was supported by Tenovus (T15/59) that provided funded the role of HW. DM is supported 19 
by a Wellcome Trust Clinical Research Development Fellowship (Grant 214588/Z/18/Z). DM is a member 20 
of the European Medicines Agency Pharmacovigilance Risk Assessment Committee. BJL reports grants 21 
and personal fees from Sanofi, AstraZeneca, and Teva; reports personal fees from Cipla, Glenmark, and 22 











Background: Angiotensin converting enzyme inhibitor (ACEI) intolerance commonly occurs requiring 25 
switching to an angiotensin-II receptor blocker (ARB). ACEI intolerance may be mediated by bradykinin 26 
potentially affecting airway hyper-responsiveness.  27 
Objective: Assess the risk of switching to ARBs in asthma. 28 
Methods: We conducted a new-user cohort study of ACEI initiators identified from electronic health 29 
records from the UK Clinical Practice Research Datalink. The risk of switching to ARBs in people with 30 
asthma, chronic obstructive pulmonary disease (COPD) and the general population were compared. 31 
Adjusted hazard ratios (HR) were calculated using Cox regression, stratified by British Thoracic Society 32 
(BTS) treatment step and ACEI type. 33 
Results: Of 642,336 new-users of ACEI, 6.4% had active asthma. The hazard of switching to ARB was 34 
greater in people with asthma (HR1.16, 95%CI 1.14-1.18, p=<0.001) and highest in those at BTS step ≥3 35 
(HR1.35, 95%CI 1.32-1.39 and 1.18, 95%CI 1.15-1.22, p=<0.001 for patients aged ≥60 years and <60 36 
years respectively). Hazard was highest with enalapril (HR1.25, 95%CI 1.18-1.34, p=<0.001; HR1.44, 37 
95%CI 1.32-1.58, p=<0.001 for BTS step ≥3 asthma). No increased hazard was observed in COPD or those 38 
younger than 60 years at BTS step 1/2. The NNT varied by age, gender and BMI ranging between 21 and 39 
4, being lowest in older women with BMI ≥25. 40 
Conclusions: People with active asthma are more likely to switch to ARBs after commencing ACEI 41 
therapy.  The NNT varies by age, gender, BMI and BTS step. ARBs could potentially be considered first-42 









Highlights box 44 
1: What is already known on this topic? 45 
 Many people are intolerant to ACE inhibitors due to cough and require switching to an 46 
angiotensin-II receptor blocker (ARB). 47 
 ACE inhibitors may affect airway hyperresponsiveness in asthma, possibly mediated via 48 
bradykinin or cough reflex sensitivity. 49 
2: What does this article add to our knowledge? 50 
 People with asthma are generally at increased risk of switching to ARBs from ACEI therapy and is 51 
greatest in those with more severe asthma. 52 
 The absolute risk of switching varies by age, sex and body mass index. 53 
3: How does this study impact current management guidelines? 54 
 ARBs could be considered first-line in older people with asthma or young people with more 55 
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Asthma is a highly prevalent disease causing significant morbidity, mortality and healthcare cost.[1] 80 
Comorbidity in asthma is common, and 62.6% of people with asthma reported to have ≥1 comorbidity, 81 
and the likelihood of having coronary artery disease, congestive heart failure, peripheral vascular 82 
disease, cerebrovascular disease, hypertension, diabetes and chronic kidney disease are all significantly 83 
greater in people with asthma compared to the general population.[2,3] Angiotensin-converting enzyme 84 
inhibitors (ACEI) are commonly prescribed medicines indicated for the management of these chronic 85 
diseases.[4] ACEI block the enzyme responsible for converting the peptide hormone angiotensin-I to 86 
angiotensin-II, which stimulates aldosterone release and causes vasoconstriction. Whilst ACEI have 87 
beneficial effects in the management of these chronic diseases, many patients are intolerant of long-88 
term ACEI the most common reason of which is a dry persistent cough. This adverse drug reaction is 89 
thought to occur in around 10% of people treated with ACEI and may be related to increased levels of 90 
bradykinin.[5] This adverse reaction is considered a class effect of ACEI, suggesting that even low doses 91 
may also alter bradykinin levels in susceptible patients. 92 
 93 
In people who develop ACEI intolerance from cough it is recommended that patients are switched to 94 
angiotensin-II receptor blocker (ARB) therapy.[5] ARBs have similar properties to ACEI but do not cause a 95 
persistent dry cough. ARBs inhibit angiotensin-II in a highly selective manner via a mechanism which 96 
does not alter bradykinin levels. However, irrespective of the cause having to switch treatments 97 
increases healthcare resource utilisation, treatment burden, treatment disutility, and may delay in 98 
establishing effective preventative therapy for the underlying indication.  Despite being an important 99 
health economic factor many drug formularies and guidelines still recommend first-line treatment with 100 
ACEIs usually on cost grounds.[6] 101 
 102 
A key tenet in the pathogenesis of asthma is airway hyper-responsiveness (AHR) which can be affected 103 
by a variety of environmental stimuli.[7,8] Bradykinin is a pro-inflammatory mediator that can cause 104 
bronchoconstriction and lung inflammation.[9] It is therefore plausible that treatment with ACEI  may 105 
exacerbate asthma symptoms through bradykinin accumulation leading to worsening AHR, which may in 106 
turn increase the incidence of cough and switching to ARBs.[10] However, there is limited evidence 107 
studying the effect of ACEI exposure in patients with asthma. The aim of this study was to 1) examine 108 
ACEI drug utilisation in people with asthma, 2) assess the association of switching to ARBs in people with 109 











Data source 112 
The UK Clinical Practice Research Datalink (CPRD) GOLD database was used to identify a large UK cohort 113 
of people with active asthma. CPRD GOLD contains anonymised electronic medical records from >680 114 
general practices covering >5 million people in the UK with linked health data about patient 115 
demographics, prescriptions, diagnoses, hospitalisations and deaths. Patients are broadly representative 116 
of the UK general population in terms of age, sex and ethnicity.[11] General practices and patients 117 
within CPRD GOLD are required to meet defined quality standards in order to contribute data, with 118 
diagnoses have high validity, including for asthma that has a positive predictive value for respiratory 119 
disease of around 90%.[12,13] It has also been deemed to meet regulatory requirements to be used in a 120 
regulatory context.[14] 121 
 122 
Study cohort 123 
An open cohort of adults aged 18 years and over was identified from January 1 1998 through to June 30 124 
2014. This time period reflects the start of database availability and the latest data available at the time 125 
of data extraction. Patients were required to be registered with a general practice providing up-to-126 
standard data for at least 1 year prior to cohort entry. The population was divided into patients with 127 
active asthma with the remainder forming the rest of the general population. People with active asthma 128 
were defined using a validated code list for asthma and the receipt of at least two asthma medications 129 
with cohort follow-up commencing at the latest of these dates.[13] Asthma medicines were defined by 130 
the use of: inhaled short-acting beta2-agonists (SABA); inhaled corticosteroids (ICS); inhaled long-acting 131 
beta2-agonists (LABA); oral leukotriene antagonists (LKTA); and oral methylxanthines.[15] To reduce the 132 
chance of misclassification, people with a diagnostic code for asthma who also had a diagnostic code for 133 
COPD, interstitial lung disease or bronchiectasis were excluded from the active asthma population. For 134 
examining drug utilisation, cohort exit (that results in right censoring) for all patients was defined as the 135 
earliest of the following: end of study period; deregistration from the general practice; date of last data 136 
collection from the general practice; or death. For the analysis examining the risk of switching to an ARB 137 
following ACEI initiation, cohort entry was additionally defined by the date of the incident ACEI 138 
prescription in people without any prior ACEI or ARB exposure and cohort exit was additionally defined 139 
by the date of switching to an ARB or 180 days after ACEI discontinuation if no ARB had been initiated. 140 
For the switching analysis, patients prescribed an ARB on or prior to the incident ACEI were excluded. To 141 










patients with COPD who acted as a negative control population. Patients with COPD are expected to be 143 
unaffected by the underlying pathophysiological hypothesis targeting AHR and were identified also using 144 
a validated code list.[16] 145 
 146 
Exposures 147 
All ACEI and ARB prescriptions were identified for patients within the cohort. The date of incident ACEI 148 
therapy was defined as the first ever ACEI prescription occurring during cohort follow-up with no 149 
previous prescription at any point prior to this time. ACEI discontinuation was defined by the date of an 150 
ACEI prescription with no further ACEI prescription following at least six months of this date. Switching 151 
to an ARB was defined by an incident ARB prescription issued within six months of the ACEI 152 
discontinuation date, with the date of the ACEI discontinuation representing day 1 of this six month 153 
period of follow-up (Online Repository Figure E1). The list of ACEI and ARB drug codes are provided in 154 
the Online Repository Table E1. For people who switched, the maximal ACEI dose prescribed prior to 155 
switching was calculated. ACEI doses were standardised using ramipril equivalent doses (please see 156 
Online Repository Table E2). 157 
 158 
Outcomes 159 
The primary outcome was the relative hazard of switching from ACEI to ARB therapy in people with 160 
active asthma compared to the general population, with trends in ACEI initiation and switching to ARBs 161 
reported over the study period among the active asthma population. Patients could switch at any point 162 
after initiating ACEI therapy providing they met the definition of switching and had not been censored 163 
due to one of the cohort exit criteria. 164 
 165 
Analysis 166 
Trends in the quarterly prevalence of ACEI and ARB initiation and discontinuation were calculated for 167 
the active asthma population. The start of each quarter was defined as January 01, April 01, July 01 and 168 
October 01. The quarterly prevalence was age-standardised using the European standard 169 
population.[17] The cohort analysis used Cox proportional hazards regression to calculate hazard ratios 170 
(HR) for switching to an ARB after initiating ACEI therapy in people with asthma compared to the general 171 
population. Time in this time to event analysis was the difference in days between the date of the 172 
incident ACEI prescription and switching to an ARB or another cohort exit censoring event as described 173 










plots. We used the entire population available to use within the database that met our criteria. Based 175 
upon a two-group survival analysis this cohort has 90% at alpha 0.01 to detect a difference in relative 176 
hazard of 1.05 or greater. The Cox model was adjusted for the following baseline confounders: age; sex; 177 
practice-level socioeconomic deprivation applied to the individual (defined by the Index of Multiple 178 
Deprivation categorised into quintiles); smoking status (categorised into smoker, ex-smoker and non-179 
smoker); body mass index (BMI, categorised into <20, 20-24, ≥25); history of cardiovascular disease 180 
(CVS); and history of hypertension. We selected variables based upon a search in the literature, known 181 
differences in the characteristics of asthma patients and indications for ACEI. A full model was fitted 182 
with using all variables as main effects. The active asthma cohort was categorized into three groups 183 
according to baseline British Thoracic Society (BTS) asthma treatment step (1, 2 and ≥3) defined by 184 
prescribed asthma medication as a potential marker of severity and included in the model.[1] The 185 
cohort was stratified by the most frequently prescribed types of ACEI and analysed separately. Multiple 186 
imputation was used to impute missing data on BMI, deprivation and smoking status. The imputation 187 
model included all variables relating to clinical characteristics, medication exposure and switching 188 
events. Multiple imputation used fully conditional specification, with linear regression for continuous 189 
variables and logistic regression for categorical variables with five imputations analysed using Rubin’s 190 
rules.[18] We performed a complete case analysis to assess the impact of multiple imputation as a 191 
sensitivity analysis. To calculate an absolute measure, the rate of switching per 1000 patients was first 192 
calculated in the general cohort population, and was then multiplied by the adjusted hazard ratio to 193 
calculate the expected number of switchers in asthma. The number of asthma patients needed to treat 194 
(NNT) with an ACEI for one person to switch to an ARB was then calculated by taking the reciprocal of 195 











The active asthma cohort consisted of 521,857 adults (57.8% female, mean age 39 years) of which 198 
66,895 patients (12.8%) were prescribed ACEIs, 28,791 were prescribed ARBs (5.5%), and 16,203 were 199 
prescribed both (3.1%) individually at some point during cohort follow-up. Trends in ACEI and ARB 200 
prescribing are presented in the Online Repository Figure E2.  201 
 202 
Among the entire population, a total of 642,336 patients initiating ACEIs were identified, of which 203 
40,953 had active asthma (6.4%). The remainder formed the general population, of which 5.2% had 204 
COPD. Patient characteristics are shown in table 1. Fewer patients with active asthma were men, current 205 
smokers or had a history of CVS disease. The most commonly prescribed ACEIs were ramipril, followed 206 
by lisinopril, perindopril then enalapril. Overall, 17.4% of people with active asthma switched to an ARB 207 
following ACEI initiation compared to 14.6% from the general population. Among those who switched, 208 
the number of GP consultations and mean ramipril10-equivalent dose prior to switching were similar 209 
between the groups.  210 
 211 
The hazard ratio for switching to an ARB in patients with active asthma was increased compared to the 212 
general population (HR 1.16, 95%CI 1.14-1.18) (table 2). In contrast it was decreased for patients with 213 
COPD (HR 0.89, 95%CI 0.87-0.91). When associations between other patient characteristics were 214 
examined, the hazard of switching to an ARB was greater in women compared to men (HR 1.46, 95%CI 215 
1.45-1.47), with increasing age (HR 1.65, 95%CI 1.62-1.71 for patients ≥60 years) and in patients with 216 
BMI ≥25 (table 2). In contrast, the hazard of switching to an ARB was lower in patients with a history of 217 
smoking and in patients registered at general practices in more socioeconomically deprived areas.  218 
 219 
The increased hazard of switching to an ARB with active asthma was similar when stratified by gender 220 
(HR 1.16, 95%CI 1.13-1.19 for men and HR 1.17, 95%CI 1.15-1.20 for women). Hazard ratios for 221 
switching to an ARB were greater among active asthma patients aged ≥60 years and among those at BTS 222 
step ≥3 (HR 1.35, 95%CI 1.32-1.39 and HR 1.18, 95%CI 1.15-1.22 for patients aged ≥60 years and <60 223 
years respectively) (figure 1 and table 3). While the hazard ratio was elevated among asthma patients 224 
aged ≥60 years at BTS step 1 and 2, no increased hazard was observed for those aged <60 years. When 225 
stratified by the four most commonly prescribed ACEIs, the hazard ratio for switching to an ARB in 226 
patients with active asthma was consistently elevated for all ACEI types, being numerically largest with 227 










sensitivity analysis using a complete case analysis were in keeping with the main results (Online 229 
Repository Table E3). 230 
 231 
The overall incidence of switching to an ARB in the general population was 148 per 1000 patients with 232 
an additional 24 per 1000 patients (95%CI 21-27) among people with active asthma. The NNT with an 233 
ACEI for one person to switch to an ARB varied by age, sex, BMI and asthma severity (table 5). The NNT 234 
in men with BMI <20 varied from 24 to 11 being lower with older patients at BTS step 3. Corresponding 235 
numbers for men with BMI of ≥25 were lower ranging from 12 to 6 respectively. The NNT similarly 236 
varied in women, ranging from 14 to 7 in women with BMI <20 and from 10 to 4 in women with BMI of 237 
≥25, being lower in older patients at BTS step 3. Corresponding numbers for the general population are 238 











Summary of findings 241 
We observed that people with active asthma have an increased risk of ACEI intolerance and switching to 242 
ARB therapy compared to the general population. This association was greatest in those with more 243 
severe asthma, with people above and below 60 years of age at BTS step ≥3 asthma having a 35% 244 
increased hazard versus 18% increased hazard respectively. The hazard of switching to an ARB was 245 
consistently elevated with all commonly prescribed ACEIs in our population and was largest following 246 
treatment with enalapril, with BTS step ≥3 patients having a 44% increased hazard. However, patients 247 
below 60 years of age at BTS step 1 or 2 asthma were not at increased risk. The number of asthma 248 
patients needed to treat with ACEI for one person to switch was also significantly influenced by age, sex 249 
and BMI, which ranged from 21 to 4, being lowest in older women with a BMI of ≥25 at BTS step 3. 250 
 251 
Comparison with previous literature 252 
AHR is an important determinant in the pathophysiology of asthma and is affected by a variety of stimuli 253 
such as methacholine and bradykinin that can cause bronchoconstriction,.[7,8] Whereas methacholine 254 
induces bronchoconstriction in normal and in asthmatic subjects, bradykinin-induced 255 
bronchoconstriction is predominantly observed in asthmatics, suggesting the effect of bradykinin is 256 
related to structural and/or to functional airway abnormalities that occur in asthma.[7] Bradykinin’s 257 
potent bronchoconstrictor effect in asthmatic patients is thought to be mediated via an indirect 258 
mechanism related to the level of AHR and active airway inflammation.[9,10] Whilst the increased 259 
hazard of switching in people with active asthma, but not COPD, would be in keeping with a specific 260 
effect on AHR other mechanisms such as ACEI increasing cough reflex hypersensitivity, which is similarly 261 
associated with female gender, cannot be excluded.[21] 262 
 263 
Indirect acting  AHR is related to the degree of aeroallergen sensitisation and occurs independently of 264 
airway calibre or ICS use.[22] This in turn may explain why the effect of bradykinin due to ACEI may be 265 
specific for asthma but not COPD, in addition to the presence of type 2 inflammation in the former. This 266 
is because AHR is not a key feature in the pathogenesis of COPD perhaps unless patients have asthma-267 
COPD overlap syndrome. Indeed, fixed airway remodelling in COPD may be one reason why a decreased 268 
hazard of switching was observed in this population. Our observation of increased ACEI intolerance in 269 
patients with BTS step 3 and above is likely explained by such patients have more severe disease. Having 270 










patients taking step 3/4 therapy.[23-25] Some studies have evaluated bronchial reactivity of captopril, 272 
ramipril and enalapril in asthma patients and showed no change in reactivity.[26-31] However, the 273 
cumulative number of patients from all of these studies is only n=71, which in addition to studies 274 
employing different methods (ie. histamine, bradykinin or methacholine challenges or simply measuring 275 
lung function) limits the generalisability of these findings. 276 
 277 
Although several types of ACEIs are available for clinical use, it cannot be assumed they are all equally 278 
effective or safe without head to head comparisons. In our study the hazard of switching to ARB with 279 
enalapril was modestly larger in people with asthma compared to other ACEI. In a meta-analysis of 280 
randomized controlled trials, ACEI cough had higher rates in hypertension and lowest rates in heart 281 
failure suggesting these may differ by underlying cardiovascular condition.[32] Although differences 282 
among users of different ACEI types remains possible, we adjusted for several of these factors and saw a 283 
larger hazard ratio for hypertension compared to cardiovascular disease. Similarly, a network meta-284 
analysis of 29 randomized placebo controlled trials of ACEI therapy in heart failure patients also found 285 
that enalapril had the highest incidence of cough, gastrointestinal discomfort, and greater deterioration 286 
in renal function compared to other ACEIs.[33] 287 
 288 
An increased risk of cough or switching to ARB therapy in people with asthma has recently been 289 
reported.[32,34]  However, no studies used an active asthma population, examined associations by 290 
asthma severity or type of ACEI, or provided information relating to ACEI dose or the rate of healthcare 291 
utilisation rate prior to switching. Meanwhile information on absolute risk is lacking but is necessary to 292 
guide robust health economic and clinical decision is making.  Women in the general population are 293 
considered to have a 1.5 to 2.3-fold increased risk of switching to ARBs following ACEI therapy.[35-37]  294 
However, the impact of increasing age has been less consistently reported and there remains a paucity 295 
of data around the association with BMI.[38-40]  We clearly show that all three characteristics are 296 
relevant for people with asthma and are strong determinants of the NNT. 297 
 298 
Strengths and limitations 299 
This study has several strengths and limitations. First we analysed a large clinical population identified 300 
using a validated data source and definitions. Although cough is by far the most common reason for 301 
ACEI intolerance and switching to an ARB we were unable to directly measure ACEI-induced cough as an 302 










between cough related to ACEIs as opposed to another condition, particularly in patients with asthma. 304 
Whilst cough is the predominant reason for ACEI intolerance in the general population, we cannot 305 
exclude the possibility that other symptoms such as wheeze or dyspnoea may have occurred, which 306 
have been reported among asthma patients using ACEIs.[40] However, switching to an ARB after ACEI 307 
treatment is considered to be the best marker for identifying ACEI-induced adverse drug reactions in 308 
electronic databases, having a positive predictive value of up to 90.5% with cough being the most 309 
commonly reported adverse reaction.[42,43]  310 
 311 
Whist there remains the potential for unmeasured confounding from potentially important unknown 312 
patient factors not included in our model, we used a negative control population by examining the 313 
association in patients with COPD. The null findings in patients with COPD provide additional evidence 314 
suggesting our observed association is causal and that the increased hazard of switching observed in 315 
people with active asthma are potentially related to changes in AHR due to bradykinin. However, these 316 
results may not be generalizable to people with the asthma-COPD overlap syndrome. It would be 317 
pertinent to further evaluate the putative impact of ACEI in patients with known AHR and markers of 318 
type 2 inflammation such as fractional exhaled nitric oxide and blood eosinophils, as well as total and 319 
specific IgE levels.[44,45] 320 
 321 
Clinical implications 322 
It is recognised that managing comorbidities in patients with asthma may be associated with additional 323 
risk.[46-49] When evaluated for the management of hypertension, ARBs are thought to have similar 324 
effects on blood pressure, mortality and CVS outcomes compared with ACEIs, yet fewer patients in the 325 
general population withdraw from clinical trials due to adverse effects when treated with ARBs 326 
compared to ACEIs.[50] Despite the potentially higher incidence of switching with enalapril, the largest 327 
determinant on absolute risk in people with asthma appeared to be a person’s age, gender and BMI. 328 
Given the high prevalence of obesity in the population combined with increasing age of patients, such 329 
factors are important determinants for considering whether ARBs should be recommended as first line 330 
therapy. This would be particularly relevant in people with asthma, where discriminating ACEI-induced 331 
cough from symptoms of uncontrolled asthma may be complex, potentially leading to unnecessary 332 
asthma treatment if not immediately recognised. Many guidelines for the management of patients with 333 
cardiovascular disease still recommend ACEIs as first-choice therapy, reserving ARBs as an alternative 334 










given the equal efficacy but fewer adverse reactions with ARBs.[51] This would potentially avoid 336 
unnecessary health care appointments, patient treatment disutility, and delays in establishing effective 337 
therapy for the underlying clinical condition.  338 
 339 
In conclusion, our findings suggest that ACEIs are less well tolerated in people with asthma compared to 340 
the general population. The NNT is lower in asthma and in those with older age, are female and have a 341 
higher BMI. Consideration could potentially be given to recommending ARBs first-line in people with 342 
asthma or those with high risk characteristics when treatment with a renin-angiotensin system inhibitor 343 
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Table 1. Demographic details and baseline covariates of people initiating ACEI therapy in the general population and in 506 




Active asthma cohort 
(n = 40953) 
General population 
(n = 601383) 
Mean age, (SD) 58.7 (13.3) 64.4 (13.8) 
Male sex (%) 17274 (42.2) 315463 (52.5) 
Mean years of follow-up (SD) 3.0 (3.3) 3.3 (3.4) 
Mean BMI at baseline (SD) 30.7 (6.7) 28.7 (5.9) 
    Missing BMI (%) 1314 (3.2) 39519 (6.6) 
Practice level deprivation (%):   
    1 (least deprived) 3712 (8%) 55612 (9.3) 
    2 5510 (14%) 81311 (13.5) 
    3 5273 (13%) 79094 (13.2) 
    4 5329 (13%) 87680 (14.6) 
    5 (most deprived) 5115 (13%) 77959 (13.0) 
    Missing 16014 (39.1) 219727 (36.5) 
COPD (%) 0 (0) 31294 (5.2) 
Hypertension (%) 27783 (67.8) 401,918 (66.8) 
Cardiovascular disease (%) 8090 (19.8) 169805 (28.2) 
Baseline smoking status (%)   
    Non-smoker 20918 (55.7) 256732 (49.2) 
    Ex-smoker 11537 (30.7) 167358 (32.1) 
    Current smoker 5129 (13.7) 98001 (18.8) 
    Missing smoking status (%) 3369 (8.2) 79292 (13.2) 
ACEI type (%)   
    Ramipril 22600 (55.2) 324942 (54.0) 
    Lisinopril 10279 (25.1) 148389 (24.7) 
    Perindopril 5741 (14.0) 91054 (15.1) 
    Enalapril 1907 (4.7) 28760 (4.8) 
    Other* 426 (1.0) 8238 (1.4) 
Number discontinuing ACEIs (%) 18973 (46.3) 271773 (45.2) 
Number switching to an ARB (%) 7108 (17.4) 88980 (14.8) 
Mean ACEI dose mg (SD)* 4.4 (2.9) 4.5 (3.0) 
Mean no. GP consultations (SD)** 12.4 (21.1) 12.0 (18.9) 
*Other = quinapril, trandolapril, captopril, fosinopril, imidapril, cilazapril or moexipril. **Standardised ramipril 509 
equivalent dose prior to switching. ***Mean number of general practice (GP) surgery consultations between the 510 
date of ACEI initiation and ARB initiation. SD=standardised difference. P-value for all comparisons <0.05 using Chi-511 










Table 2. Hazard ratios for switching to an ARB following any ACEI therapy in people with active asthma compared to 513 
the general population and other risk factors. 514 




Adjusted Hazard ratio 
(95% CI) 
Adjusted   
P-value 
Population     
    General population 1.00  1.00  
    Active asthma 1.22 (1.20-1.24) <0.001 1.16 (1.14–1.18) <0.001 
    COPD 0.79 (0.78-0.81) <0.001 0.89 (0.87-0.91) <0.001 
Hypertension 1.34 (1.33-1.35) <0.001 1.21 (1.20–1.22) <0.001 
Cardiovascular disease 0.81 (0.80-0.82) <0.001 0.88 (0.87-0.89) <0.001 
Sex     
    Male 1.00  1.00  
    Female 1.53 (1.52-1.54) <0.001 1.46 (1.45-1.47) <0.001 
Age at baseline      
    <40 1.00  1.00  
    40-49 1.34 (1.30-1.37) <0.001 1.32 (1.29-1.36) <0.001 
    50-59 1.53 (1.50-1.57) <0.001 1.53 (1.49-1.57) <0.001 
    >60 1.67 (1.63-1.71) <0.001 1.66 (1.62-1.70) <0.001 
BMI category     
    <20 1.00  1.00  
    20-24 1.37 (1.34-1.40) <0.001 1.43 (1.39-1.46) <0.001 
    >=25 1.52 (1.49-1.56) <0.001 1.55 (1.51-1.59) <0.001 
Smoking status     
    Non-smoker 1.00  1.00  
    Ex-smoker  0.89 (0.88-0.90) <0.001 0.96 (0.95–0.97) <0.001 
    Current smoker 0.64 (0.63-0.65) <0.001 0.73 (0.72–0.74) <0.001 
Deprivation     
    1 (Least deprived) 1.00  1.00  
    2 1.07 (1.05-1.08) <0.001 1.05 (1.04-1.06) <0.001 
    3 1.13 (1.12-1.14) <0.001 1.10 (1.09-1.11) <0.001 
    4 1.17 (1.15-1.18) <0.001 1.13 (1.12-1.15) <0.001 
    5 (Most deprived) 1.24 (1.22-1.25) <0.001 1.20 (1.18-1.21) <0.001 
BTS step=British Thoracic Society asthma treatment step. Adjusted model adjusted for gender, age, BMI, smoking 515 
status, history of hypertension, cardiovascular disease, COPD and socioeconomic deprivation. Deprivation=Index of 516 










Table 3. Overall adjusted cause-specific hazard ratios for  switching to an ARB following ACEI therapy stratified by 518 
British Thoracic Society asthma treatment step. 519 














Age >=60 years      
  ≥3 9057 (45.6) 1.47 (1.44-1.51) <0.001 1.35 (1.32-1.39) <0.001 
  2 5774 (29.1) 1.22 (1.18-1.26) <0.001 1.13 (1.09-1.17) <0.001 
  1 5026 (25.3) 1.23 (1.19-1.28) <0.001 1.14 (1.09-1.19) <0.001 
Age <60 years      
  ≥3 9398 (44.6) 1.27 (1.23-1.30) <0.001 1.18 (1.15-1.22) <0.001 
  2 4982 (23.6) 1.09 (1.05-1.14) <0.001 1.02 (0.96-1.07) 0.753 
  1 6716 (31.8) 0.97 (0.94-1.01) 0.193 0.96 (0.92-1.00) 0.146 
BTS step=British Thoracic Society asthma treatment step. Adjusted model adjusted for gender, age, BMI, smoking status, 520 










Table 4. Overall adjusted cause-specific hazard ratios for  switching to an ARB following different types of ACEI 522 
therapy. 523 
                                                           
ACEI type 








Enalapril     
   BTS step ≥3 1.51 (1.39-1.64) <0.001 1.44 (1.32-1.58) <0.001 
   BTS step 2 1.29 (1.16-1.42) <0.001 1.21 (1.08-1.35) <0.001 
   BTS step 1 1.04 (0.92-1.17) 0.582 1.01 (0.89-1.16) 0.841 
   Overall 1.31 (1.24-1.39) <0.001 1.25 (1.18-1.34) <0.001 
Ramipril     
   BTS step ≥3 1.34 (1.30-1.37) <0.001 1.27 (1.23-1.30) <0.001 
   BTS step 2 1.16 (1.12-1.20) <0.001 1.09 (1.05-1.14) <0.001 
   BTS step 1 1.05 (1.01-1.09) 0.010 1.04 (1.00-1.08) 0.060 
   Overall 1.21 (1.19-1.24) <0.001 1.16 (1.14-1.19) <0.001 
Lisinopril     
   BTS step ≥3 1.32 (1.27-1.37) <0.001 1.26 (1.21-1.31) <0.001 
   BTS step 2 1.14 (1.08-1.19) <0.001 1.09 (1.04-1.15) 0.001 
   BTS step 1 1.10 (1.04-1.16) <0.001 1.10 (1.05-1.17) <0.001 
   Overall 1.21 (1.18-1.24) <0.001 1.17 (1.14-1.21) <0.001 
Perindopril     
   BTS step ≥3 1.36 (1.30-1.43) <0.001 1.27 (1.21-1.33) <0.001 
   BTS step 2 1.09 (1.01-1.17) 0.026 1.03 (0.95-1.11) 0.456 
   BTS step 1 1.01 (0.93-1.09) 0.856 0.97 (0.89-1.05) 0.410 
   Overall 1.20 (1.16-1.25) <0.001 1.13 (1.09-1.18) <0.001 
BTS step=British Thoracic Society asthma treatment step. Adjusted model adjusted for gender, age, BMI, smoking 524 
status, history of hypertension, cardiovascular disease, COPD and socioeconomic deprivation. ACE=angiotensin 525 









Table 5. Number of asthma patients needed to treat with an ACEI for one person to switch to an ARB according 527 
to age, sex, BMI and asthma severity. 528 
 529 

























BMI <20         
   Age <40 years 9 24 24 21 74 14 14 11 
   Age 40-59 years 63 16 16 14 126 8 8 7 
   Age >=60 years 68 13 13 11 114 8 8 7 
BMI 20-24         
   Age <40 years 63 16 16 14 99 10 10 9 
   Age 40-59 years 91 11 11 9 149 7 7 6 
   Age >=60 years 114 8 8 7 176 5 5 4 
BMI >=25         
   Age <40 years 82 12 12 10 101 10 10 8 
   Age 40-59 years 118 9 9 7 171 6 6 5 
   Age >=60 years 135 7 7 6 192 5 5 4 
Rate=Rate of switching to an ARB following ACEI initiation. BMI=Body mass index. NANT=Number with asthma needed to 530 
treat with ACEI for a switch to ARB to occur. NNT calculated taking the reciprocal of rate in non-asthma population*hazard 531 
ratio of switching in asthma by age and BTS step, rounded to the nearest whole number. Step=British Thoracic Society 532 













Figure Legends 538 
 539 
Figure 1. Kaplan-Meier failure plots for risk of switching to an ARB following treatment with ACEI in A) people 540 
under 60 years with asthma, B) people under 60 years by BTS treatment step, C) people aged 60 years or older 541 






























Supplementary Figure Legends 
 
Figure E1. Diagram demonstrating the exposure windows used to define switching to ARB 
therapy following initiation of ACEI therapy. 
 
Figure E2. Age-standardized quarterly prevalence of ACEIs and ARBs in patients with active 
asthma. 
ACE=angiotensin converting-enzyme inhibitor. ARB=angiotensin-II receptor blocker. Q=quarter. 
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